Effect of cocaine use on buprenorphine pharmacokinetics in humans

American Journal on Addictions

Volumn 19, Issue 1, 2010, Pages 38-46

  McCance Katz, Elinore F ^a,d   Rainey, Petrie M ^b   Moody, David E ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF UTAH   (United States)

^d SAN FRANCISCO GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; COCAINE; DIAMORPHINE; NALOXONE;

ADULT; ADVERSE OUTCOME; AREA UNDER THE CURVE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EXPOSURE; DRUG USE; FEMALE; HALF LIFE TIME; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; RETROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE;

ADULT; BUPRENORPHINE; COCAINE; DRUG INTERACTIONS; FEMALE; HUMANS; MALE;

EID: 77149148755     PISSN: 10550496     EISSN: 15210391     Source Type: Journal    
DOI: 10.1111/j.1521-0391.2009.00001.x     Document Type: Article

References (46)

1. Leri F, Bruneau J, Stewart J. Understanding polydrug use: Review of heroin and cocaine co-use. Addiction. 2003 98 : 7 22.
2. Hasin DS, Grant BF, Endicott J, et al. Cocaine and heroin dependence compared in polydrug abusers. Am J Public Health. 1988 8 : 567 569.
3. Schottenfeld RS, O'Malley S, Abdul-Salaam K, et al. Decline in intravenous drug use among treatment-seeking opiate users. J Subst Abuse Treat. 1993 10 : 5 10.
4. Schutz CG, Vlahov D, Anthony JC, et al. Comparison of self-reported injection frequencies for past 30 days and 6 months among intravenous drug users. J Clin Epidemiol. 1994 47 : 191 195.
5. Grella CE, Anglin MD, Wugalter SE. Patterns and predictors of cocaine and crack use by clients in standard and enhanced methadone maintenance treatment. Am J Drug Alcohol Abuse. 1997 23 : 15 42.
6. McCance-Katz EF. Office based treatment of opioid dependence with buprenorphine. Harv Rev Psychiatry. 2004 12 : 321 338.
7. Walsh SL, Preston KL, Stitzer ML, et al. Clinical pharmacology of buprenorphine: Ceiling effects at high doses. Clin Pharmacol Ther. 1994 55 : 569 580.
8. Black JL, Dolan MP, Penk WE, et al. The effect of increased cocaine use on drug treatment. Addict Behav. 1987 12 : 289 292.
9. Disney ER, Kidorf M, King VL, et al. Prevalence and correlates of cocaine physical dependence subtypes using the DSM-IV in outpatients receiving opioid agonist medication. Drug Alcohol Depend. 2005 79 : 23 32.
10. Kosten T, Sofuoglu M, Poling J, et al. Desipramine treatment for cocaine dependence in buprenorphine- or methadone-treated patients: Baseline urine results as predictor of response. Am J Addict. 2005 14 : 8 17.
11. Kosten TR, Rounsaville BJ, Kleber HD. A 2.5-year follow-up of cocaine use among treated opioid addicts. Have our treatments helped Arch Gen Psychiat. 1987 44 : 281 284.
12. Chang Y, Moody DE, McCance-Katz EF. Novel metabolites of buprenorphine detected in human liver microsomes and human urine. Drug Metab Dispos. 2006 34 : 440 448.
13. Picard N, Cresteil T, Djebli N, et al. In vitro metabolism study of buprenorphine: Evidence for new metabolic pathways. Drug Metab Dispos. 2005 33 : 689 695.
14. Zhang W, Ramamoorthy Y, Tyndale RF, et al. Interaction of buprenorphine and its metabolite norbuprenorphine with cytochromes p450 in vitro. Drug Metab Dispos. 2003 31 : 768 772.
15. Kobayashi K, Yamamoto T, Chiba K, et al. Human buprenorphine N-dealkylation is catalyzed by cytochrome P450 3A4. Drug Metab Dispos. 1998 26 : 818 821.
16. Iribarne C, Picart D, Dréano Y, et al. Involvement of cytochrome P450 3A4 in N-dealkylation of buprenorphine in human liver microsomes. Life Sci. 1997 60 : 1953 1964.
17. Maurer HH, Sauer C, Theobald DS. Toxicokinetics of drugs of abuse: Current knowledge of the isoenzymes involved in the human metabolism of tetrahydrocannabinol, cocaine, heroin, morphine, and codeine. Ther Drug Monit. 2006 28 : 447 453.
18. Laizure SC, Mandrell T, Gades NM, et al. Cocaethylene metabolism and interaction with cocaine and ethanol: Role of carboxylesterases. Drug Metab Dispos. 2003 31 : 16 20.
19. Brzezinski MR, Spink BJ, Dean RA, et al. Human liver carboxylesterase hCE-1: Binding specificity for cocaine, heroin, and their metabolites and analogs. Drug Metab Dispos. 1997 25 : 1089 1096.
20. Dean RA, Christian CD, Sample RH, et al. Human liver cocaine esterases: Ethanol-mediated formation of ethylcocaine. FASEB J. 1991 5 : 2735 2739.
21. Kloss MW, Rosen GM, Rauckman EJ. N-demethylation of cocaine to norcocaine. Evidence for participation by cytochrome P-450 and FAD-containing monooxygenase. Mol Pharmacol. 1983 23 : 482 485.
22. LeDuc BW, Sinclair PR, Shuster L, et al. Norcocaine and Nhydroxynorcocaine formation in human liver microsomes: Role of cytochrome P-450 3A4. Pharmacology. 1993 46 : 294 300.
23. Pellinen P, Kulmala L, Konttila J, et al. Kinetic characteristics of norcocaine N-hydroxylation in mouse and human liver microsomes: Involvement of CYP enzymes. Arch Toxicol. 2000 74 : 511 520.
24. McCance-Katz EF, Moody DE, Morse GD, et al. Interactions between buprenorphine and antiretrovirals I: The nonnucleoside reverse-transcriptase inhibitors efavirenz and delavirdine. Clin Infect Dis. 2006a 43 (Suppl 4 S224 234.
25. McCance-Katz EF, Moody DE, Morse G, et al. Interactions between buprenorphine and antiretrovirals II: Protease inhibitors, nelfinavir, lopinavir/ritonavir, or ritonavir. Clin Infect Dis. 2006 43 (Suppl 4 S235 46.
26. McCance-Katz EF, Moody DE, Morse GD, et al. Interaction between buprenorphine and atazanavir or atazanavir/ritonavir. Drug Alcohol Depend. 2007 91 : 269 278.
27. Huang W, Moody DE, McCance-Katz EF. The in vivo glucuronidation of buprenorphine and norbuprenorphine determined by liquid chromatography- electrospray ionization-tandem mass spectrometry. Ther Drug Monit. 2006 28 : 245 251.
28. Lopez P, Velez R, Rivera V. Characteristics of P-glycoprotein (Pgp) upregulated in chronic cocaine users and HIV infected persons. Retrovirology. 2005 2 (Suppl 1 142.
29. Pellinen P, Stenbäck F, Kojo A, et al. Regenerative changes in hepatic morphology and enhanced expression of CYP2B10 and CYP3A during daily administration of cocaine. Hepatology. 1996 23 : 515 523.
30. Brogan WC, Lange RA, Glamann DB, et al. Recurrent coronary vasoconstriction caused by intranasal cocaine: Possible role for metabolites. Ann Intern Med. 1992 116 : 556 561.
31. Kurth CD, Monitto C, Albuquerque ML, et al. Cocaine and its metabolites constrict cerebral arterioles in newborn pigs. J Pharmacol Exp Ther. 1993 265 : 587 591.
32. Madden JA, Powers RH. Effect of cocaine and cocaine metabolites on cerebral arteries in vitro. Life Sci. 1990 47 : 1109 1114.
33. Madden JA, Konkol RJ, Keller PA, et al. Cocaine and benzoylecgonine constrict cerebral arteries by different mechanisms. Life Sci. 1995 56 : 679 686.
34. Elkader A, Sproule B. Buprenorphine: Clinical pharmacokinetics in the treatment of opioid dependence. Clin Pharmacokinet. 2005 44 : 661 680.
35. Mendelson J, Upton RA, Everhart ET, et al. Bioavailability of sublingual buprenorphine. J Clin Pharmacol. 1997 37 : 31 37.
36. Kuhlman JJ, Lalani S, Magluilo J, et al. Human pharmacokinetics of intravenous, sublingual, and buccal buprenorphine. J Anal Toxicol. 1996 20 : 369 378.
37. Bastoe ML, Jukovsky D, Mule SJ. Routine identification of cocaine metabolites in human urine. J Chromatogr. 1974 89 : 335.
38. Kolbrich EA, Barnes AJ, Gorelick DA, et al. Major and minor metabolites of cocaine in human plasma following controlled subcutaneous cocaine administration. J Anal Toxicol. 2006 30 : 501 510.
39. Preston KL, Goldberger BA, Cone EJ. Occurrence of cocaine in urine of substance abuse treatment patients. J Anal Toxicol. 1998 22 : 580 586.
40. Moolchan ET, Cone EJ, Wstadik A, et al. Cocaine and metabolite elimination patterns in chronic cocaine users during cessation: Plasma and saliva analysis. J Anal Toxicol. 2000 24 : 458 466.
41. Preston KL, Epstein DH, Cone EJ, et al. Urinary elimination of cocaine metabolites in chronic cocaine users during cessation. J Anal Toxicol. 2002 26 : 393 400.
42. Jufer RA, Wstadik A, Walsh SL, et al. Elimination of cocaine and metabolites in plasma, saliva, and urine following repeated oral administration to human volunteers. J Anal Toxicol. 2000 24 : 467 477.
43. Foltin RW, Fischman MW. Effects of methadone or buprenorphine maintenance on the subjective and reinforcing effects of intravenous cocaine use in humans. J Pharmacol Exp Ther. 1996 278 : 1153 1164.
44. Foltin RW, Fischman MW. Effects of buprenorphine on the self-administration of cocaine by humans. Behav Pharmacol. 1994 5 : 79 89.
45. Montoya ID, Gorelick DA, Preston KL, et al. Randomized trial of buprenorphine for treatment of concurrent opiate and cocaine dependence. Clin Pharmacol Ther. 2004 75 : 34 48.
46. Fiellin DA, Sullivan L, Moore BC, et al. The impact of cocaine use on outcomes in office-based buprenorphine treatment [abstract College on Problems of Drug Dependence, 2008 San Juan, PR.